Samsca Post-marketing General Drug Use-results Survey in Patients with Hyponatremia in SIADH

Launched by OTSUKA PHARMACEUTICAL CO., LTD. · Mar 7, 2021

Keywords

ClinConnect Summary

This clinical trial is studying a medication called tolvaptan, which is used to help manage a condition known as hyponatremia caused by the syndrome of inappropriate antidiuretic hormone secretion (SIADH). In simpler terms, this condition occurs when your body has too much of a hormone that helps control water balance, leading to low sodium levels in the blood. The aim of the trial is to confirm that tolvaptan is safe for patients dealing with this issue in Japan.

To participate in this study, individuals must have a confirmed diagnosis of SIADH according to specific medical guidelines. The trial is open to all adults, and there are currently no limitations based on age or gender. If you join the study, you can expect to be monitored for how well the medication works and any side effects it may cause. The researchers are eager to ensure that tolvaptan is a safe and effective option for people facing this challenging condition.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Subjects with a definite diagnosis of SIADH in reference to "Diagnostic and Treatment Manual of the Hypersecretion of Vasopressin (SIADH), Revised in 2018"
• Exclusion Criteria:
• • -